NCT03520036 - Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

July 5, 2018

Primary Completion Date

September 28, 2019

Study Completion Date

September 28, 2019

Conditions

Erythropoietic Protoporphyria (EPP)

Interventions

DRUG

MT-7117 low dose

MT-7117 low dose QD, oral, 16 weeks

DRUG

MT-7117 high dose

MT-7117 high dose QD, oral, 16 weeks

DRUG

Placebo

Placebo QD, oral, 16 weeks

Trial Locations (9)

Ichan School of Medicine at Mount Sinai, New York

Wake Forest Baptist Medical Center, Winston-Salem

University of Miami Miller School of Medicine, Miami

Remington-Davis, Inc, Columbus

University of Texas Medical Branch Porphyria Center, Galveston

University of Utah, Salt Lake City

ACTCA, A Member of the Alliance, Inc., Los Angeles

University of California at San Francisco, San Francisco

Metro Boston Clinical Partners, LLC, Brighton